radiotherapy combined with nedaplatin and 5-FU for postoperative locoregional recurrent esophageal cancer -phase II study-

radiotherapy combined with nedaplatin and 5-FU for postoperative locoregional recurrent esophageal cancer -phase II study- - chemoradiotherapy for postoperative locoregional recurrent esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018360

Enrollment

Registered

2015-07-21

Start date

2000-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative locoregional (excluding hematogenous metastasis) recurrent esophageal cancer

Interventions

chemoradiotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3, 2) no other active cancer, 3) no serious cardiac, liver, or pulmonary disease, 4) creatinine clearance of more than 50 ml/min, 5) adequate bone marrow function (leukocyte count of 4000/ul, platelet count of 100,000/ul, 6) locoregional recurrence (including para-aortic lymph node metastasis) without distant metastasis after no residual tumor (R0) resection; extended radical esophagectomy with three-field (neck, mediastinum, and abdomen) lymph node dissection, and 7) no previous therapy other than R0 resection.

Exclusion criteria

Exclusion criteria: see above

Design outcomes

Primary

Measure	Time frame
overall survival rate	—

Secondary

Measure	Time frame
tumor response, relapse-free survival rate, irradiated-field control rate and toxicity	—

Countries

Japan

Contacts

Public Contactsee above

see above see above

kjingu-jr@rad.med.tohoku.ac.jp-81-22-717-7312

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026